Literature DB >> 27785654

Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.

Michael J Campbell1, Frederick Baehner2, Tess O'Meara3, Ekene Ojukwu3, Booyeon Han3, Rita Mukhtar4, Vickram Tandon3, Max Endicott3, Zelos Zhu3, Jasmine Wong4, Gregor Krings2, Alfred Au2, Joe W Gray5, Laura Esserman4,3.   

Abstract

PURPOSE: The recent increase in the incidence of ductal carcinoma in situ (DCIS) has sparked debate over the classification and treatment of this disease. Although DCIS is considered a precursor lesion to invasive breast cancer, some DCIS may have more or less risk than is realized. In this study, we characterized the immune microenvironment in DCIS to determine if immune infiltrates are predictive of recurrence.
METHODS: Fifty-two cases of high-grade DCIS (HG-DCIS), enriched for large lesions and a history of recurrence, were age matched with 65 cases of non-high-grade DCIS (nHG-DCIS). Immune infiltrates were characterized by single- or dual-color staining of FFPE sections for the following antigens: CD4, CD8, CD20, FoxP3, CD68, CD115, Mac387, MRC1, HLA-DR, and PCNA. Nuance multispectral imaging software was used for image acquisition. Protocols for automated image analysis were developed using CellProfiler. Immune cell populations associated with risk of recurrence were identified using classification and regression tree analysis.
RESULTS: HG-DCIS had significantly higher percentages of FoxP3+ cells, CD68+ and CD68+PCNA+ macrophages, HLA-DR+ cells, CD4+ T cells, CD20+ B cells, and total tumor infiltrating lymphocytes compared to nHG-DCIS. A classification tree, generated from 16 immune cell populations and 8 clinical parameters, identified three immune cell populations associated with risk of recurrence: CD8+HLADR+ T cells, CD8+HLADR- T cells, and CD115+ cells.
CONCLUSION: These findings suggest that the tumor immune microenvironment is an important factor in identifying DCIS cases with the highest risk for recurrence and that manipulating the immune microenvironment may be an efficacious strategy to alter or prevent disease progression.

Entities:  

Keywords:  Breast; DCIS; Immune microenvironment

Mesh:

Substances:

Year:  2016        PMID: 27785654      PMCID: PMC5225037          DOI: 10.1007/s10549-016-4036-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  38 in total

1.  Rethinking the Standard for Ductal Carcinoma In Situ Treatment.

Authors:  Laura Esserman; Christina Yau
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

2.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

Authors:  B Fisher; J Dignam; N Wolmark; E Mamounas; J Costantino; W Poller; E R Fisher; D L Wickerham; M Deutsch; R Margolese; N Dimitrov; M Kavanah
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

Authors:  Steven A Narod; Javaid Iqbal; Vasily Giannakeas; Victoria Sopik; Ping Sun
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

4.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Authors:  N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

Review 5.  Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.

Authors:  Rita A Mukhtar; Onouwem Nseyo; Michael J Campbell; Laura J Esserman
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

Review 6.  Ductal carcinoma in situ of the breast: current concepts and future directions.

Authors:  Kalliopi P Siziopikou
Journal:  Arch Pathol Lab Med       Date:  2013-04       Impact factor: 5.534

7.  Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.

Authors:  M Sharma; A H Beck; J A Webster; I Espinosa; K Montgomery; S Varma; M van de Rijn; K C Jensen; R B West
Journal:  Breast Cancer Res Treat       Date:  2009-12-01       Impact factor: 4.872

8.  Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).

Authors:  Sylvia Adams; Lori J Goldstein; Joseph A Sparano; Sandra Demaria; Sunil S Badve
Journal:  Oncoimmunology       Date:  2015-07-27       Impact factor: 8.110

9.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes.

Authors:  Anne E Carpenter; Thouis R Jones; Michael R Lamprecht; Colin Clarke; In Han Kang; Ola Friman; David A Guertin; Joo Han Chang; Robert A Lindquist; Jason Moffat; Polina Golland; David M Sabatini
Journal:  Genome Biol       Date:  2006-10-31       Impact factor: 13.583

10.  Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.

Authors:  Minoru Miyashita; Hironobu Sasano; Kentaro Tamaki; Hisashi Hirakawa; Yayoi Takahashi; Saki Nakagawa; Gou Watanabe; Hiroshi Tada; Akihiko Suzuki; Noriaki Ohuchi; Takanori Ishida
Journal:  Breast Cancer Res       Date:  2015-09-04       Impact factor: 6.466

View more
  35 in total

Review 1.  Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-09       Impact factor: 3.875

Review 2.  Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Authors:  Vidya C Sinha; Helen Piwnica-Worms
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

Review 3.  Ductal carcinoma in situ of breast: update 2019.

Authors:  Sunil S Badve; Yesim Gökmen-Polar
Journal:  Pathology       Date:  2019-08-28       Impact factor: 5.306

4.  Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Authors:  Marie Colombe Agahozo; Mieke R van Bockstal; Floris H Groenendijk; Thierry P P van den Bosch; Pieter J Westenend; Carolien H M van Deurzen
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

Review 5.  Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression.

Authors:  Andrew C Nelson; Heather L Machado; Kathryn L Schwertfeger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-08-31       Impact factor: 2.673

Review 6.  Immune microenvironment in different molecular subtypes of ductal breast carcinoma.

Authors:  Mona Sadeghalvad; Hamid-Reza Mohammadi-Motlagh; Nima Rezaei
Journal:  Breast Cancer Res Treat       Date:  2020-10-03       Impact factor: 4.872

Review 7.  Cancer overdiagnosis: a biological challenge and clinical dilemma.

Authors:  Sudhir Srivastava; Eugene J Koay; Alexander D Borowsky; Angelo M De Marzo; Sharmistha Ghosh; Paul D Wagner; Barnett S Kramer
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

Review 8.  The Role of Innate Immunity in the Pathogenesis of Breast Cancer.

Authors:  Damir Grebić; Tamara Gulić; Alma Starčević; Manuela Alvirović; Gordana Blagojević Zagorac; Petra Valković Zujić; Danijela Veljković Vujaklija
Journal:  Breast Care (Basel)       Date:  2020-05-04       Impact factor: 2.860

Review 9.  Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer.

Authors:  Anita K Mehta; Sapana Kadel; Madeline G Townsend; Madisson Oliwa; Jennifer L Guerriero
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

10.  Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System.

Authors:  Anne Trinh; Carlos R Gil Del Alcazar; Sachet A Shukla; Koei Chin; Young Hwan Chang; Guillaume Thibault; Jennifer Eng; Bojana Jovanović; C Marcelo Aldaz; So Yeon Park; Joon Jeong; Catherine Wu; Joe Gray; Kornelia Polyak
Journal:  Mol Cancer Res       Date:  2020-12-18       Impact factor: 6.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.